Is CL a Buy or a Sell? The Bull and Bear Case (2026)

That depends on which case you find more convincing, and both are on this page. The bull case rests on Oral-care leadership and emerging markets, with revenue (ttm) at ~$20 billion. The bear case rests on colgate's growth is structurally slow: it competes in mature, saturated staples categories where volume gains are hard to come by and much of recent revenue growth has come from price increases that may not persist. Analysts covering it are spread from $85.00 to $110.00, which is itself a signal that this is genuinely contested. If you believe the thesis, the real questions become sizing and overlap rather than timing. Walnut is not an investment adviser and this is not a recommendation.

Nobody can answer that for you, and the honest version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. Colgate's growth is structurally slow: it competes in mature, saturated staples categories where volume gains are hard to come by and much of recent revenue growth has come from price increases that may not persist. If that risk is what you were worried about and it is now playing out, that is a real signal. If the price simply fell while the thesis held, that is a different situation entirely. The most pessimistic published target is $85.00, -8.2% from the $92.60 price, which is one analyst's downside case rather than a floor. Walnut is not an investment adviser.

Oral-care leadership and emerging markets. Colgate holds a leading global share in toothpaste and a strong position in toothbrushes and mouthwash, with deep penetration in emerging markets across Latin America, Africa, and Asia. The most optimistic analyst target on CL is $110.00, +18.8% from the $92.60 price. That figure is only reachable if this thesis works close to its best case.

Colgate's growth is structurally slow: it competes in mature, saturated staples categories where volume gains are hard to come by and much of recent revenue growth has come from price increases that may not persist. It faces intense competition from Procter and Gamble, Unilever, and private-label brands, plus pressure from retailers. Heavy emerging-market exposure brings currency volatility that can erode reported results. Input-cost inflation, the rise of private label during cost-of-living squeezes, and the challenge of sustaining pricing without losing volume all weigh on the outlook. The defensive premium valuation can also compress when investors rotate toward higher-growth or cyclical names. The most pessimistic published target is $85.00, -8.2% from the current price, which is roughly what the stock is worth if these risks bite rather than the drivers.

Defensive consumer-staples leader in oral care plus Hill's pet nutrition, with a multi-decade Dividend King record.

Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (Oral-care leadership and emerging markets) stalling in the reported numbers rather than in the narrative, the risk above (colgate's growth is structurally slow: it competes in mature, saturated staples categories where volume gains are hard to come by and much of recent revenue growth has come from price increases that may not persist) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.

CL, listed on the New York Stock Exchange. The company is Colgate-Palmolive Company, headquartered in New York City. It trades during US market hours and is available at every major US brokerage.

Colgate-Palmolive makes everyday consumer products: oral care (Colgate toothpaste and toothbrushes), personal care (Palmolive, Softsoap, Irish Spring), home care (dish and surface cleaners), and pet nutrition through Hill's. It sells these branded staples in more than 200 countries.

In oral and personal care, Procter and Gamble, Unilever, Church and Dwight, and Haleon. In home care, Reckitt and Clorox. In pet nutrition, Mars and Nestle Purina compete with Hill's.